Title:
Bisarylimidazoly fatty acid amide hydrolase inhibitors
Document Type and Number:
United States Patent RE39634

Abstract:
The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.

Inventors:
Sit, Sing-yuen (Meriden, CT, US)
Xie, Kai (Wallingford, CT, US)
      Plaque It!

Application Number:
10/883195
Publication Date:
05/15/2007
Filing Date:
07/01/2004
View Patent Images:
Images are available in PDF form when logged in. To view PDFs, Login  or  Create Account (Free!)
Export Citation:
Click for automatic bibliography generation
Assignee:
Bristol-Myers Squibb Company (Princeton, NJ, US)
Primary Class:
514/341
Other Classes:
546/275.100, 514/399, 548/341.500, 548/338.100, 548/336.100
International Classes:
A61K31/4164; A61K31/4439; C07D233/64; C07D401/12
Field of Search:
514/341, 546/275.1, 548/336.1, 548/341.5, 548/338.1, 514/399
US Patent References:
5648373CoA-IT and PAF inhibitorsJuly, 1997Winkler et al.
Other References:
Levine, “New Directions in Pain Research: Molecules to Maladies,” Neuron, vol. 20, pp. 649-654, Apr. 1998.
Pasternak, “The Central Questions in Pain Perception May Be Peripheral,” Proc. Natl. Acad. Sci., USA, vol. 95, pp. 10354-10355, Sep. 1998.
Devane, et al., “Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor,” Science, vol. 258, pp. 1946-1949, Dec. 18, 1992.
Hanus, et al., “Two New Unsatured Fatty Acid Ethanolamides in Brian That bind to the Cannabinoid Receptor,” J. Med. Chem., vol. 36, pp. 3032-3034, 1993.
Mechoulam, et al., “Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors,” Biochem. Pharmacol., vol. 50, No. 1, pp. 83-90, 1995.
Barg, et al., “Cannabinomimetic Behavioral Effects of and Adenylate Cyclase Inhibition by Two New Endogenous Anandamides,” European Journal of Pharmacology, vol. 287, pp. 145-152, 1995.
Richardson, et al., “Cannabinoids Reduce Hyperalgesia and Inflammation Via Interaction with Peripheral CB1 Receptors,” Pain, vol. 75, pp. 111-119, 1998.
Jaggar, et al., “The Anti-hyperalgesic Actions of the Cannabiniod Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain,” Pain, vol. 76, pp. 189-199, 1998.
Huang, et al., “Identification of New Class of Molecules, the Arachidonyl Amide Acids, and Characterization of One Member That Inhibits Pain,” Journal of Biological Chemistry, vol. 276, No. 46, pp. 42639-42644, 2001.
Richardson, et al., “Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependant Hyperalgesia,” Journal of Neuroscience, vol. 18, No. 1, pp. 451-457, 1998.
Calignano, et al., “Control of Pain Initiation by Endogenous Cannabinoids,” Nature, vol. 394, pp. 277-280, Jul. 16, 1998.
Meng, et al., “An Analgesia Circuit Activated by Cannabinoids,” Nature, vol. 395, pp. 381-383, Sep. 24, 1998.
Meanwell, et al., “Nonprostanoid Prostacyclin Mimetics. 3. Structural Variations of the Diphenyl Heterocycle Molety,” Journal of Medicinal Chemistry, 1992, vol. 35, pp. 3498-3512.
Primary Examiner:
Stockton, Laura L.
Attorney, Agent or Firm:
Makujina, Shah R.
Parent Case Data:

CROSS REFERENCE TO RELATED APPLICATION

This non-provisional application claims priority from provisional application U.S. Ser. No. 60/286,827 filed Apr. 27, 2001.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a reissue application of U.S. Pat. No. 6,562,846, issued May 13, 2003, on non-provisional application No. 10/128,480, filed Apr. 23, 2002 which claims priority from provisional application USSN 60/286,827 filed Apr. 27, 2001.

Claims:
What is claimed is:

1. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3 alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

2. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is HYC(O)O; X is C and is attached to A; Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

3. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H; C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

4. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is C3-7cycloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

5. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is —C1-2alkylene-phenyl said —C1-2alkylene-phenyl is optionally substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

6. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is phenyl or —C1-2alkylene-phenyl, said phenyl or phenyl of said —C1-2alkylene-phenyl are optionally substituted with the same or different substitutents selected from the group consisting of halo, CN, —C(O)O—C1-3-alkyl, C1-3alkyl and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

7. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is phenyl or —C1-2alkylene-phenyl, said phenyl or phenyl of said —C1-2alkylene-phenyl are substituted with halo, —C(O)O—C1-3-alkyl, C1-3alkyl or C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

8. Compound of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is phenyl or —C1-2alkylene-phenyl, said phenyl or phenyl of said —C1-2alkylene-phenyl are substituted with fluoro; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

9. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3 alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is phenyl or —C1-2alkylene-phenyl, said phenyl or phenyl of said —C1-2alkylene-phenyl are substituted with cyano; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

10. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each H; R3 is C1-C3alkyl; A is C7-10alkylene; D is HYC(O)O; Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; and G′ is H, C1-5alkyl or C1-5haloalkyl.

11. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each H; R3 is C1-C3alkyl; A is C1-5alkylene; D is HYC(O)O; Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

12. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each H; R3 is C1-C3alkyl; A is C7-10alkylene; D is HYC(O)ON═C(G′); Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; and G′ is H, C1-5alkyl or C1-5haloalkyl.

13. Compounds of Formula (I) embedded image and pharmaceutically acceptable salts and solvates thereof wherein R1 are R2 are each H; R3 is C1-C3alkyl; A is C1-5alkylene; D is HYC(O)ON═C(G′); Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substitutents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12 alkylene.

14. [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; [6-(2-Ethyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid tert-butyl ester; 6-(2-Ethyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid sec-butyl ester; [6-(2-Ethyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid sec-butyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid benzyl ester; 2-Propanone, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 2-Propanone, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid methyl ester; 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-fluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2,4-difluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-chloro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-methoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid o-tolyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-cyano-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2,6-dimethoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-methoxy-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid methyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid ethyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-fluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2-fluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2,4-difluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-chloro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-methoxy-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid o-tolyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-cyano-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2,6-dimethoxy-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2-methoxy-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid ethyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-fluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2,4-difluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2-fluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-chloro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-methoxy-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid o-tolyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-cyano-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2,6-dimethoxy-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2-methoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 3,4-difluoro-phenyl ester; {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1-yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester; {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1-yl]-hexyl}-carbamic acid 2,6-difluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid ethyl ester; Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 4-Fluorobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 4-Fluorobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 2-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 2-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethoxy]-phenyl}-carbamic acid 3,4-difluoro-phenyl ester; {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethoxy]-phenyl}-carbamic acid 4-chloro-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 3,4-difluoro-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 4-methoxy-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 4-chloro-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 2-methoxy-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 3-chloro-phenyl ester; {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethoxy]-phenyl}-carbamic acid phenyl ester; {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethoxy]-phenyl}-carbamic acid 2-fluoro-phenyl ester; {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethoxy]-phenyl}-carbamic acid 4-fluoro-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid phenyl ester; {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethoxy]-phenyl}-carbamic acid 4-methoxy-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 2-fluoro-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 2,6-difluoro-phenyl ester; {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethoxy]-phenyl}-carbamic acid ethyl ester; [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; [1-Ethyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; [1-Isopropyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; or [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-1-phenyl-hexyl]-carbamic acid 2-fluoro-phenyl ester or a pharmaceutically acceptable salt or solvate thereof.

15. [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; 2-Propanone, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 2-Propanone, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid cyclohexyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid methyl ester; 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-fluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2,4-difluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-chloro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-methoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid o-tolyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-cyano-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2,6-dimethoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-methoxy-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid methyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid ethyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-fluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2-fluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2,4-difluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-chloro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-methoxy-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid o-tolyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-cyano-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2,6-dimethoxy-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2-methoxy-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid ethyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-fluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2,4-difluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2-fluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-chloro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-methoxy-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid o-tolyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-cyano-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2-methoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 3,4-difluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid isopropyl ester; {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1-yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester; {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1-yl]-hexyl}-carbamic acid 2,6-difluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid ethyl ester; Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 4-Fluorobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 4-Fluorobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 2-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 2-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 3,4-difluoro-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 4-methoxy-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 4-chloro-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 2-methoxy-phenyl ester; {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propoxy]-phenyl}-carbamic acid 3-chloro-phenyl ester; [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; [1-Ethyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; [1-Isopropyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; or [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-1-phenyl-hexyl]-carbamic acid 2-fluoro-phenyl ester or a pharmaceutically acceptable salt or solvate thereof.

16. [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; 2-Propanone, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 2-Propanone, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-fluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2,4-difluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-chloro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-methoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid o-tolyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-cyano-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid ethyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-fluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2-fluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2,4-difluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-chloro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-methoxy-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid o-tolyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-cyano-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2-methoxy-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-fluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2,4-difluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2-fluoro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-chloro-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-methoxy-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 4-cyano-phenyl ester; [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]-carbamic acid 2,6-dimethoxy-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 3,4-difluoro-phenyl ester; {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1-yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester; {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1-yl]-hexyl}-carbamic acid 2,6-difluoro-phenyl ester; Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 4-Fluorobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 4-Fluorobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 2-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 2-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]carbonyl]oxime; 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexylaminocarbonyl]oxime; [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; or [1-Ethyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester or a pharmaceutically acceptable salt or solvate thereof.

17. [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester; 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-fluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2,4-difluoro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 4-chloro-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid o-tolyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 2-fluoro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-chloro-phenyl ester; [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]-carbamic acid 4-cyano-phenyl ester; [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 3,4-difluoro-phenyl ester; {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1-yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester; or [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester or a pharmaceutically acceptable salt or solvate thereof.

18. A method of treating chronic pain, acute pain or neuropathic pain in a mammal in need thereof by the administration of an effective amount of a pharmaceutical composition comprising a compound according to claims 1, 2, 3 or 4.

19. A method of treating chronic pain, acute pain and neuropathic pain by the administration of a pharmaceutical composition comprising embedded image or a pharmaceutically acceptable salt or solvate thereof.

20. A method of treating neuropathic pain by the administration of a pharmaceutical composition comprising embedded image or a pharmaceutically acceptable salt or solvate thereof.

21. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is phenyl or —C1-2alkylene-phenyl, said phenyl or phenyl of said —C1-2alkylene-phenyl are substituted with fluoro; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12alkylene.

22. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is phenyl or —C1-2alkylene-phenyl, said phenyl or phenyl of said —C1-2alkylene-phenyl are substituted with cyano; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12alkylene.

23. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; D is X(O)O; X is C and is attached to A; and G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substituents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy.

24. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene; D is HYC(O)ON═C(G′); Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substituents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; and G′ is H, C1-5alkyl or C1-5haloalkyl.

25. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is —C1-2alkylene-phenyl, said —C1-2alkylene-phenyl is optionally substituted with one or more of the same or different substituents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12alkylene.

26. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each independently H, C1-3alkyl or halo; R3 is C1-C3alkyl or C3-7cycloalkyl; A is C1-12alkylene or L; L is -phenyl-O—C1-4alkylene wherein said C1-4alkylene is attached to D; provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′); X is C and is attached to A; Y is N and is attached to A; G is phenyl or —C1-2alkylene-phenyl, said phenyl or phenyl of said —C1-2alkylene-phenyl are optionally substituted with one or more of the same or different substituents selected from the group consisting of halo, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C1-3alkylene; wherein Z is O or S and is attached to A; J is CH and is attached to A, D and J′; J′ is C1-4alkyl or phenyl; provided that if A—D is interrupted with —Z-phenyl-, then A is C1-5alkylene; if A—D is not interrupted with —Z-phenyl-, then A is C5-12alkylene.

27. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each H; R3 is C1-C3alkyl; A is C7-10alkylene; D is HYC(O)O; Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substituents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy.

28. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each H; R3 is C1-C3alkyl; A is C1-5alkylene; D is HYC(O)O; Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substituents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxyl and C1-3alkoxy; and wherein A—D is interrupted with —Z-phenyl-; wherein Z is O or S and is attached to A.

29. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each independently H; R3 is C1-C3alkyl; A is C7-10alkylene; D is HYC(O)ON═C(G′); Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substituents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxyl and C1-3alkoxy; and G′ is H, C1-5alkyl or C1-5haloalkyl.

30. A compound of Formula (I) embedded image or a pharmaceutically acceptable salt or solvate thereof wherein R1 and R2 are each H; R3 is C1-C3alkyl; A is C1-5alkylene; D is HYC(O)ON═C(G′); Y is N and is attached to A; G is H, C1-5alkyl, C1-5haloalkyl, C3-7cycloalkyl, phenyl, —C1-2alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C1-2alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substituents selected from the group consisting of halo, NO2, CN, —C(O)O—C1-3-alkyl, C1-3alkyl, hydroxy and C1-3alkoxy; G′ is H, C1-5alkyl or C1-5haloalkyl; and wherein A—D is interrupted with —Z-phenyl-; wherein Z is O or S and is attached to A.

31. A method of treating chronic pain, acute pain or neuropathic pain in a mammal in need thereof by the administration of an effective amount of a pharmaceutical composition comprising a compound according to claims 21, 22 or 23-30.

Description:

FIELD OF THE INVENTION

The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase and are useful for the treatment of conditions affected by inhibiting fatty acid amide hydrolase.

BACKGROUND

Neuropathic pain is caused by injury to nerves as the result of many factors including physical damage (e.g., trauma, surgery), drugs such as Zidovudine (AZT), Carmustine (BCNU) and disease (e.g., diabetes, herpes zoster). The prevalence in the United States of neuropathies associated with diabetes, herpes and amputation is estimated at 1.5 million. The worldwide prevalence of diabetic neuropathy alone is expected to reach 12 million by 2007. Nerve injury can result in both allodynia and hyperalgesia.

Current treatment of neuropathic pain involves the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and acetaminophen) and other analgesics as well as anticonvalsants (e.g., carbamazepine, gabapentin) and tricyclic antidepressants (e.g., amitryptiline). Effective treatment of pain with current therapies is limited by adverse effects and a lack of efficacy against all components of pain.

Current research is aimed at understanding the molecular and physiological components of pain processing to develop more effective analgesics (Levin, J. D., New Directions in Pain Research: Meeting Report Molecules to Maladies, Neuron 20: 649-654, 1998; Pastemak, G. W., The Central Questions in Pain Perception May Be Peripheral, PNAS 95:10354-10355, 1998).

The analgesic properties of cannabinoids have been known for many years and to many cultures. Cannabinoids are active in many pre-clinical models of pain, including neuropathic pain. Within the last few years, several endogenous cannabinoids, including the fatty acid amides arachidonylethanolamide (anandamide), and arachidonyl amino acids such as N-arachidonylglycine, homo-γ-linolenyl-ethanolamide and docosatetraenyl-ethanolamide, as well as 2-arachidonyl-glycerol, have been shown to induce analgesia in laboratory animals (De Vane, W.A. et. al., Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptors, Science 258: 1946-1949, 1992; Hanus, L. et. al., Two New Unsaturated Fatty Acid Ethanolamides in Brain that Bind to the Cannabinoid Receptor, J. Med. Chem. 36: 3032-3034, 1993; Machoulam, R. et. al., Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds To Cannabinoid Receptors, Biochem. Pharmacol. 50: 83-90, 1995; Vogel, Z. et. al., Cannabinomimetic Behavioral Effects of and Adenylate Cyclase Inhibition By Two New Endogenous Anandamides, Eur. J. Pharmacol. 287: 145-152, 1995; Hargreaves, K. M. et al., Cannabinoids Reduce Hyperalgesia and Inflammation Via Interaction With Peripheral CB1 Receptors, Pain 75: 111-119, 1998; Rice,A. S. C., et. al., The Anti-Hyperalgesic Actions of the Cannabinoid Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain, Pain 76: 189-199, 1998; Huang, S. M., et al., Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain, J. Biological Chemistry, 276: 46, 42639-42644, 2001). The ability of cannabinoid receptor antagonists and cannabinoid receptor antisense to induce hyperalgesia in animals suggests that endogenous cannabinoids regulate the nociceptive threshold (Hargreaves, K. M. et al., Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia, J. Neurosci. 18: 451-457, 1998; Piomelli, D. et. al., Control of Pain Initiation By Endogenous Cannabinoids, Nature 394: 277-281, 1998; Fields, H. L. et. al., An Analgesia Circuit Activated By Cannabinoids, Nature 395: 381-383, 1998). Elevation of levels of neuroactive fatty acid amides such as anandamide may provide a unique mechanism to achieve analgesia. The mechanisms by which endogenous cannabinoids are synthesized are not well understood; therefore, target for drugs aimed at increasing the synthesis of these compounds are slow to be identified.

Anandamide and the other identified endogenous cannabinoids are inactivated through a cleavage mechanism by a membrane-bound enzyme, fatty acid amide hydrolase (FAAH). FAAH, therefore, provides an important target for regulating the activity of endogenous cannabinoids. The inhibition of FAAH may elevate levels of anandamide or other endogenous cannabinoids to increase the nociceptive threshold. Furthermore, the inhibition of FAAH would also extend the therapeutic benefits of other cannabinoid agoinsts in the treatment of emesis, anxiety, feeding, behaviors, movement disorders, glaucoma, neuroprotection and cardiovascular disease.

SUMMARY OF THE INVENTION

Thus according to a first embodiment of the first aspect of the present invention are provided compounds of Formula (I) embedded image
and pharmaceutically acceptable salts and solvates thereof wherein

R 1 are R 2 are each independently H, C 1-3 alkyl or halo;

R 3 is C 1 -C 3 alkyl or C 3-7 cycloalkyl;

A is C 1-12 alkylene or L;

      • L is -phenyl-O—C 1-4 alkylene wherein said C 1-4 alkylene is attached to D;
      • provided that if A is L, then D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene;
    • D is X(O)O, X(O)N(G′), HYC(O)O or HYC(O)ON═C(G′);
      • X is C and is attached to A;
      • Y is N and is attached to A;
    • G is H, C 1-5 alkyl, C 1-5 haloalkyl, C 3-7 cycloalkyl, phenyl, —C 1-2 alkylene-phenyl, C-pyridyl or N-pyridyl, said phenyl or —C 1-2 alkylene-phenyl are each optionally and independently substituted with one or more of the same or different substituents selected from the group consisting of halo, NO 2 , CN, —C(O)O—C 1-3 -alkyl, C 1-3 alkyl, hydroxy and C 1-3 alkoxy;

G′ is H, C 1-5 alkyl or C 1-5 haloalkyl;

    • wherein A—D is optionally interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene;
    • wherein
    • Z is O or S and is attached to A;
    • J is CH and is attached to A, D and J′;
    • J′ is C 1-4 alkyl or phenyl; and
    • provided that
    • if A—D is interrpted with —Z-phenyl-, then A is C 1-5 alkylene;
    • if A—D is not interrpted with —Z-phenyl-, then A is C 5-12 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each halo.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each fluoro.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 3 is methyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 3 is ethyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is L.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 3-10 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 7-10 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 4-8 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 5-7 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 8-9 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 9 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 6 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A is C 1-4 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein D is X(O)O.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein D is X(O)N(G′).

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein D is HYC(O)O.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein D is HYC(O)ON═C(G′).

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein G is C 1-5 alkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein G is C 3-7 cycloalkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein G is —C 1-2 alkylene-phenyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein G is phenyl or —C 1-2 alkylene-phenyl, said phenyl or phenyl of said —C 1-2 alkylene-phenyl are optionally substituted with the same or different substituents selected from the group consisting of halo, CN, —C(O)O—C 1-3 alkyl, C 1-3 alkyl and C 1-3 alkoxy.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein G is phenyl or —C 1-2 alkylene-phenyl, said phenyl or phenyl of said —C 1-2 alkylene-phenyl are substituted with halo, —C(O)O—C 1-3 -alkyl, C 1-3 alkyl or C 1-3 alkoxy.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein G is phenyl or —C 1-2 alkylene-phenyl, said phenyl or phenyl of said —C 1-2 alkylene-phenyl are substituted with fluoro.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein G is phenyl or —C 1-2 alkylene-phenyl, said phenyl or phenyl of said —C 1-2 alkylene-phenyl are substituted with cyano.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A—D are not interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A—D are interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A—D is interrupted with J—J′.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A—D is interrupted with —Z-phenyl- .

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A—D is interrupted with —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 7-10 alkylene, D is X(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 1-5 alkylene, D is X(O)O and A—D is interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 7-10 alkylene, D is X(O)N(G′) and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 1-5 alkylene, D is X(O)N(G′) and A—D is interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 7-10 alkylene, D is HYC(O)O and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 1-5 alkylene, D is HYC(O)O and A—D is interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 7-10 alkylene, D is HYC(O)ON═C(G′) and A—D is not interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R 1 and R 2 are each H, R 3 is C 1-3 alkyl, A is C 1-5 alkylene, D is HYC(O)ON═C(G′) and A—D is interrupted with J—J′, —Z-phenyl- or —Z—C 1-3 alkylene.

According to another embodiment of the first aspect of the present invention are provided

  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2-fluoro-phenyl ester;
  • [6-(2-Ethyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-ca rbamic acid tert-butyl ester;
  • [6-(2-Ethyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-ca rbamic acid sec-butyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid benzyl ester;
  • 2-Propanone,O-[6-(2-methyl-4,5-diphenyl-1H-imidazol- 1-yl)hexyl]amino]carbonyl]oxime;
  • 2 - Propanone,O - [ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid methyl ester;
  • 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carba mic acid phenyl ester;
  • [ 6 -( 2 - Methyl - 4 , 5 - diphenyl - imidazol - 1 - yl )- hexyl ]- carbamic acid phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-fluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2,4-difluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-chloro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-methoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid o-tolyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-cyano-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2,6-dimethoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2-methoxy-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl-carb amic acid methyl ester;
  • [ 7 -( 2 - Methyl - 4 , 5 - diphenyl - imidazol - 1 - yl )- heptyl ]- carbamic acid methyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid ethyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-fluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2-fluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2,4-difluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-chloro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-methoxy-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid o-tolyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-cyano-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2,6-dimethoxy-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2-methoxy-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid ethyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-fluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2,4-difluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2-fluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-chloro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-methoxy-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid o-tolyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-cyano-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2,6-dimethoxy-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2-methoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 3,4-difluoro-phenyl ester;
  • {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1 -yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester;
  • {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1 -yl]-hexyl}-carbamic acid 2,6-difluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid ethyl ester;
  • Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • Benzaldehyde, O-[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 4-Fluorobenzaldehyde,O-[6-(2-methyl-4,5-diphenyl-1H- imidazol-1-yl)hexyl]amino]carbonyl]oxime;
  • 4 - Fluorobenzaldehyde,O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 2-Nitrobenzaldehye,O-[6-(2-methyl-4,5-diphenyl-1H-im idazol-1-yl)hexyl]amino]carbonyl]oxime;
  • 2 - Nitrobenzaldehye, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 3 - Nitrobenzaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 4 - Nitrobenzaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 3 - Pyridinecarboxaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethox y]-phenyl}-carbamic acid 3,4-difluoro-phenyl ester;
  • {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethox y]-phenyl}-carbamic acid 4-chloro-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 3,4-difluoro-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 4-methoxy-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 4-chloro-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 2-methoxy-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 3-chloro-phenyl ester;
  • {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethox y]-phenyl}-carbamic acid phenyl ester;
  • {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethox y]-phenyl}-carbamic acid 2-fluoro-phenyl ester;
  • {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethox y]-phenyl}-carbamic acid 4-fluoro-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid phenyl ester;
  • {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethox y]-phenyl)}-carbamic acid 4-methoxy-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 2-fluoro-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 2,6-difluoro-phenyl ester;
  • {4-[2-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-ethox y]-phenyl}-carbamic acid ethyl ester;
  • [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl) -hexyl]-carbamic acid 2-fluoro-phenyl ester;
  • [1-Ethyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)- hexyl]-carbamic acid 2-fluoro-phenyl ester;
  • [1-Isopropyl-6-(2-methyl-4,5-diphenyl-imidazol-1- yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester or
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-1-phenyl -hexyl]-carbamic acid 2-fluoro-phenyl ester.

According to another embodiment of the first aspect of the present invention are provided

  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2-fluoro-phenyl ester;
  • 2-Propanone,O-[6-(2-methyl-4,5-diphenyl-1H-imidazol- 1-yl)hexyl]amino]carbonyl]oxime;
  • 2 - Propanone,O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid cyclohexyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid methyl ester;
  • 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carba mic acid phenyl ester;
  • [ 6 -( 2 - Methyl - 4 , 5 - diphenyl - imidazol - 1 - yl )- hexyl] - carbamic acid phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-fluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2,4-difluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-chloro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-methoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid o-tolyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-cyano-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2,6-dimethoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2-methoxy-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid methyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid ethyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-fluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2-fluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2,4-difluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-chloro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-methoxy-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid o-tolyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-cyano-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2,6-dimethoxy-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2-methoxy-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid ethyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-fluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2,4-difluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2-fluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-chloro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-methoxy-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid o-tolyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-cyano-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2-methoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 3,4-difluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid isopropyl ester;
  • {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1 -yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester;
  • {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1 -yl]-hexyl}-carbamic acid 2,6-difluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid ethyl ester;
  • Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • Benzaldehyde, O-[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 4-Fluorobenzaldehyde,O-[6-(2-methyl-4,5-diphenyl-1H- imidazol-1-yl)hexyl]amino]carbonyl]oxime;
  • 4 - Fluorobenzaldehyde,O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 2-Nitrobenzaldehye,O-[6-(2-methyl-4,5-diphenyl-1H-im idazol-1-yl)hexyl]amino]carbonyl]oxime;
  • 2 - Nitrobenzaldehye, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 3 - Nitrobenzaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 4 - Nitrobenzaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 3-Pryridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 3 - Pyridinecarboxaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 3,4-difluoro-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 4-methoxy-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 4-chloro-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 2-methoxy-phenyl ester;
  • {4-[3-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-propo xy]-phenyl}-carbamic acid 3-chloro-phenyl ester;
  • [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl) -hexyl]-carbamic acid 2-fluoro-phenyl ester;
  • [1-Ethyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)- hexyl]-carbamic acid 2-fluoro-phenyl ester;
  • [1-Isopropyl-6-(2-methyl-4,5-diphenyl-imidazol-1- yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester;
  • or
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-1-phenyl -hexyl]-carbamic acid 2-fluoro-phenyl ester.

According to another embodiment of the first aspect of the present invention are provided

  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2-fluoro-phenyl ester;
  • 2-Propanone,O-[6-(2-methyl-4,5-diphenyl-1H-imidazol- 1-yl)hexyl]amino]carbonyl]oxime;
  • 2 - Propanone,O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carba mic acid phenyl ester;
  • 6 -( 2 - Methyl - 4 , 5 - diphenyl - imidazol - 1 - yl )- hexyl] - carbamic acid phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-fluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2,4-difluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-chloro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-methoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid o-tolyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-cyano-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid ethyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-fluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2-fluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2,4-difluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-chloro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-methoxy-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid o-tolyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-cyano-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2-methoxy-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-fluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2,4-difluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2-fluoro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-chloro-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-methoxy-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 4-cyano-phenyl ester;
  • [5-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-pentyl]- carbamic acid 2,6-dimethoxy-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 3,4-difluoro-phenyl ester;
  • {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1 -yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester;
  • {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1 -yl]-hexyl}-carbamic acid 2,6-difluoro-phenyl ester;
  • Benzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • Benzaldehyde, O-[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 4-Fluorobenzaldehyde,O-[6-(2-methyl-4,5-diphenyl-1H- imidazol-1-yl)hexyl]amino]carbonyl]oxime;
  • 4 - Fluorobenzaldehyde,O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 2-Nitrobenzaldehye,O-[6-(2-methyl-4,5-diphenyl-1H-im idazol-1-yl)hexyl]amino]carbonyl]oxime;
  • 2 - Nitrobenzaldehye, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 3-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 3 - Nitrobenzaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 4-Nitrobenzaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 4 - Nitrobenzaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • 3-Pyridinecarboxaldehyde, O-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]amino]car bonyl]oxime;
  • 3 - Pyridinecarboxaldehyde, O -[ 6 -( 2 - methyl - 4 , 5 - diphenyl - 1 H - imidazol - 1 - yl ) hexylaminocarbonyl]oxime;
  • [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl) -hexyl]-carbamic acid 2-fluoro-phenyl ester; or
  • [1-Ethyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)- hexyl]-carbamic acid 2-fluoro-phenyl ester.

According to another embodiment of the first aspect of the present invention are provided

  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2-fluoro-phenyl ester;
  • 6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carba mic acid phenyl ester;
  • [ 6 -( 2 - Methyl - 4 , 5 - diphenyl - imidazol - 1 - yl )- hexyl] - carbamic acid phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-fluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 2,4-difluoro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 4-chloro-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid o-tolyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 2-fluoro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-chloro-phenyl ester;
  • [7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptyl]- carbamic acid 4-cyano-phenyl ester;
  • [6-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-c arbamic acid 3,4-difluoro-phenyl ester;
  • {6-[4,5-Bis-(4-fluoro-phenyl)-2-methyl-imidazol-1 -yl]-hexyl}-carbamic acid 2-fluoro-phenyl ester;
  • or
  • [1-Methyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl) -hexyl]-carbamic acid 2-fluoro-phenyl ester.

According to various embodiments of a second aspect of the present invention are provided pharmaceutical formulations comprising compounds of Formula (I) as defined herein.

According to various embodiments of a third aspect of the present invention are provided methods of treating conditions the treatment of which can be effected by the inhibition of FAAH by the administration of pharmaceutical compositions comprising compounds of Formula (I) as defined herein.

According to another embodiment of the third aspect of the present invention is provided a method of treating pain, more particularl